Year in review: Long-term outcome of pts in the MAINRITSAN trials Better outcome in pts who received RTX every 6 months for 18 months. Implications? May consider shorter duration of maintenance tx (<36mos)? #ACR23 @RheumNow #vasculitis https://t.co/18cXBlfxSG